TrialTargeted oncology2017

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.

Neeraj Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.